This page uses content from Wikipedia and is licensed under CC BY-SA.

Depatuxizumab mafodotin

Depatuxizumab mafodotin
Monoclonal antibody
TypeWhole antibody
SourceChimeric/humanized hybrid (mouse/human)
TargetEGFR
Clinical data
Other namesABT-414
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6624H10228N1728O2052S42
Molar mass148251.25 g·mol−1

Depatuxizumab mafodotin (INN; development code ABT-414) is an antibody-drug conjugate designed for the treatment of cancer.[1][2] It is composed of an EGFR IGg1 monoclonal antibody (depatuxizumab) conjugated to the tubulin inhibitor monomethyl auristatin F via a stable maleimidocaproyl link.[3]

This drug was developed by AbbVie. In May 2019 AbbVie stopped enrolment in all studies of Depatux-M after late-stage failure in newly diagnosed glioblastoma.[4]

In 2014, Orphan Drug Status was granted by the FDA for glioblastoma multiforme.[5] It is in phase II/III clinical trials for glioblastoma, in phase II clinical trials for non-small cell lung cancer, and in phase I clinical trials for the treatment of other solid tumors.[6] Phase I results were presented at ASCO in 2016.[6]

References

  1. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Depatuxizumab Mafodotin, American Medical Association.
  2. ^ World Health Organization (2016). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 115" (PDF). WHO Drug Information. 30 (2).
  3. ^ "Antibody-drug conjugates in the spotlight - The Antibody Society". antibodysociety.org. 14 October 2016.
  4. ^ "AbbVie Provides Update on Depatuxizumab Mafodotin (Depatux-M), an Investigational Medicine for Newly Diagnosed Glioblastoma, an Aggressive Form of Brain Cancer - PM AbbVie, May 17, 2019". abbvie.com. Retrieved 20 May 2019.
  5. ^ "Depatuxizumab mafodotin". en.pharmacodia.com.
  6. ^ a b "Depatuxizumab mafodotin - AbbVie - AdisInsight". adisinsight.springer.com.